Supplement industry stakeholders see deaths reported in energy drinks AERs as a potential rallying point for Capitol Hill to consider tightening oversight of the industry. Senators Durbin and Blumenthal question FDA’s investigation of the deaths and ask for more action by the agency.
Deaths in adverse event reports for energy drink products could be a rallying cry for congressional interest in tighter FDA oversight of dietary supplements, trade group executives say.
Sens. Dick Durbin, D-Ill., and Richard Blumenthal, D-Conn., have pressed FDA on its investigation of the deaths reported in energy...
The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
A 26 June deadline looms for the final guidance even though a draft guidance was removed from the agency’s website to comply with President Trump’s gender ideology executive order. The concepts underpinning the guidance are still relevant, legal experts say.
